Cellular Protection and Regeneration in Age-Related Diseases of the Retina
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Aging".
Deadline for manuscript submissions: closed (1 February 2022) | Viewed by 534
Special Issue Editor
Special Issue Information
Dear Colleagues,
The retina is a central nervous system tissue that carries out the remarkable task of converting photons of light into complex signals to the visual cortex to create high-resolution images of our surrounding environment. There are 8 major cell types in the retina, each possessing a highly specialized structure and function, and a few of these cell types are affected in retinal diseases. The retina is susceptible to several age-related diseases, including age-related macular degeneration, glaucoma, and diabetic retinopathy.
While there are currently surgical and pharmacological treatments for these diseases, they only temporarily minimize symptoms or slow disease progression, but none prevent or eradicate these diseases. There are promising potential therapies on the horizon, but more research and development needs to be done to arrive at a cure. Research areas that offer promise for retinal diseases include reducing oxidative stress, modifying inflammatory signaling, and maintaining metabolic homeostasis and cell transplant/replacement.
The goal of this Special Issue is to highlight current multidisciplinary approaches and developments in the field of age-related diseases of the retina including pharmacology, drug delivery, and cell replacement to combat retinal cell pathology.
Dr. Raymond Scott Duncan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Retina
- Vision
- Cellular signaling
- Age-related macular degeneration
- Glaucoma
- Oxidative stress
- Inflammation
- Retinal ganglion cells
- Photoreceptors
- Retinal pigment epithelium
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
